Literature DB >> 12152915

National Kidney Disease Education Program.

Thomas H Hostetter1, Mimi Lising.   

Abstract

The predicted increase in the number of people with end-stage renal disease (ESRD) places an enormous burden on healthcare providers and the Medicare system. Recognizing this problem led the Council of American Kidney Societies to conceive, develop, and implement the National Kidney Disease Education Program (NKDEP). It was decided to aim the program at both patients and primary care providers in an attempt to halt the relentless increase in the numbers of patients with ESRD. The development of straightforward targets for therapy and screening are a goal of the NKDEP. The strategic plan of the program calls for all those at high risk of developing ESRD to seek testing. Working groups are currently addressing the components of the plan and are actively developing messages and guidance for target audiences. The NKDEP aims to reduce the incidence of ESRD. Even though the results may not come quickly, it is hoped that ESRD mortality can be reduced over the coming years.

Entities:  

Mesh:

Year:  2002        PMID: 12152915      PMCID: PMC2594171     

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  7 in total

1.  Prevention of end-stage renal disease due to type 2 diabetes.

Authors:  T H Hostetter
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

2.  Prevention of type 2 diabetes mellitus by changes in lifestyle.

Authors:  J G Fodor; K B Adamo
Journal:  N Engl J Med       Date:  2001-08-30       Impact factor: 91.245

3.  Early detection and treatment of renal disease in hospitalized diabetic and hypertensive patients: important differences between practice and published guidelines.

Authors:  W M McClellan; D F Knight; H Karp; W W Brown
Journal:  Am J Kidney Dis       Date:  1997-03       Impact factor: 8.860

4.  Slowing the progression of chronic renal failure: economic benefits and patients' perspectives.

Authors:  Hariprasad S Trivedi; Michael M H Pang; Anne Campbell; Paulette Saab
Journal:  Am J Kidney Dis       Date:  2002-04       Impact factor: 8.860

5.  Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.

Authors:  L Y Agodoa; L Appel; G L Bakris; G Beck; J Bourgoignie; J P Briggs; J Charleston; D Cheek; W Cleveland; J G Douglas; M Douglas; D Dowie; M Faulkner; A Gabriel; J Gassman; T Greene; Y Hall; L Hebert; L Hiremath; K Jamerson; C J Johnson; J Kopple; J Kusek; J Lash; J Lea; J B Lewis; M Lipkowitz; S Massry; J Middleton; E R Miller; K Norris; D O'Connor; A Ojo; R A Phillips; V Pogue; M Rahman; O S Randall; S Rostand; G Schulman; W Smith; D Thornley-Brown; C C Tisher; R D Toto; J T Wright; S Xu
Journal:  JAMA       Date:  2001-06-06       Impact factor: 56.272

6.  Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes.

Authors: 
Journal:  JAMA       Date:  2002-05-15       Impact factor: 56.272

7.  A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function.

Authors:  B L Kasiske; J D Lakatua; J Z Ma; T A Louis
Journal:  Am J Kidney Dis       Date:  1998-06       Impact factor: 8.860

  7 in total
  1 in total

1.  Chronic kidney disease: a public health problem that needs a public health action plan.

Authors:  Anton C Schoolwerth; Michael M Engelgau; Thomas H Hostetter; Kathy H Rufo; Dolph Chianchiano; William M McClellan; David G Warnock; Frank Vinicor
Journal:  Prev Chronic Dis       Date:  2006-03-15       Impact factor: 2.830

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.